BACKGROUNDApproximately 37 million people in the United States had type 2 diabetes in 2019, 1 leading to poor health, high healthcare utilization, costs, morbidity and mortality. These numbers continue to rise, highlighting the need for population-level prevention and intervention. While cohort studies have been instrumental in estimating the prevalence and incidence of diabetes as well as trends in treatment and control over time, administrative claims data are increasingly used to examine these factors. 2,3 One challenge in using administrative data is changes in practice over time, which can impact the sensitivity and specificity of claims-based definitions of health conditions.Multiple studies using Medicare data have reported on the incidence and prevalence of diabetes 2-5 as well as on trends in medication use 6 and glycaemic control. Typically, people are classified as having diabetes using a diabetes diagnosis code or-for studies which have access to prescription claims data-using a combination of International Classification of Disease (ICD) codes and medications. 7,8 The advent of new frontline medications to treat diabetes, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodiumglucose cotransporter-2 (SGLT2) inhibitors, has resulted in improvements in other heath conditions, particularly obesity, kidney disease, and congestive heart failure, which has ushered in the prescription of diabetes-related medications for new US Food and Drug Administration-approved indications as well as off-label and/or nondiabetes-specific use. This is important to consider when using administrative data since definitions of diabetes in these data often use a combination of ICD codes and/or use of specific diabetes medications.Since the prescribing patterns of these diabetes medications have changed over time-not only among people with diabetes, but among people without diabetes 9,10 as well-how investigators define diabetes when using medication lists should be revisited, particularly when dealing with data from 2010 and beyond. However, to our knowledge, no study has examined the trends in use of diabetes-related drugs over time among individuals without diabetes diagnosis codes to